Mr Mrs Miss Ms Dr Other

Dr
Laurence
Gainey

Partner & Patent Attorney

Manchester Office Alderley Park Office

Life sciences

Telephone. +44(0) 161 247 4900
Mobile. +44(0) 778 545 8684
Email. [email protected]
UPC Representative
Our team of specialist European patent litigators, oppositions specialists and patent attorneys bring together an extensive depth of legal and technical knowledge and are qualified to represent you in the UPC.

Experience

Laurence is a highly-experienced European and UK qualified patent attorney with over 25 years’ experience handling pharmaceutical and biotechnology subject matter. He has successfully managed patent portfolios on a variety of biotechnology subject matter, including diagnostic tools and targets, personalised healthcare (PHC), antisense oligonucleotide molecules, peptide and antibody (e.g. polyclonal, monoclonal, bispecific and conjugated) therapeutics, as well as handling the IP for small molecule discovery and high profile on sale pharmaceutical products, some with greater than $1bn annual sales.

After gaining a PhD in molecular biology from Reading University, Laurence joined a small biotechnology company to work in the laboratory on virus-based antigen delivery systems. After a couple of years, he moved internally to train as a patent attorney. In the same year as qualifying as European patent attorney Laurence joined the in-house patent department of AstraZeneca Pharmaceutical Ltd. where he worked for over 18 years before joining HGF’s Manchester office as a Patent Director in September 2017.

Qualifications

Patent Attorney

Chartered (UK)
Europe


BSC

Cell and Molecular Biology

PHD

Molecular Biology - Reading University

POSTGRADUATE DIPLOMA OR CERTIFICATE

Certificate in Intellectual Property Law - Queen Mary University of London

Publications

MBL Webinar entitled "Patent Due Diligence - The Fundamental Portfolio Checks Required"

View publication online

Chapter "Patent Considerations When Embarking on New Antisense Drug Programs" for the Open Access book "Antisense RNA Design, Delivery, and Analysis". "

View publication online

Related News

HGF Ranked #1 in the UK for Trade Mark Portfolios in the 2025 Trade Mark Filing Trends Report by Clarivate.

HGF has achieved the #1 ranking for the UK for trade mark portfolios in the newly released 2025 Trade mark Filing Trends report by Clarivate, recognising the firm as a …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

Quinas Technology Wins WIPO Global Award for Innovation in ICT

Our client, Quinas Technology, has been named the winner of the WIPO Global Award 2025 in the ICT Startup category. Quinas is a spin-out from Lancaster University. We have worked …

Read article

IP Ingredients: Summer Case Law Review 2025

As the British summer swings once again between sunburn and showers, it’s a great time to take stock of what the first half of the year has delivered by way …

Read article

Celebrating exam success at HGF!

We are once again delighted to share that our colleagues have achieved success in their recent exams! Their dedication, perseverance, and commitment to professional development have paid off, and we …

Read article

Is the Supreme Court denial in Thatcher’s case a fatal blow against lookalikes?

The dispute between Thatcher’s Cider Company and Aldi Stores Limited has been long running and has sparked legal controversy along the way. On 4th June 2025 the Supreme denied Aldi …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.